To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study was to determine the maximum tolerated dose (MTD) of BIBF
1120 in patients with solid tumours by the monitoring of drug-related adverse events.
Secondary objectives were the evaluation of safety, efficacy, pharmacokinetics, and
pharmacodynamics.